Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology - Pretax loss widens to GBP7.7 million for 2022 from GBP6.3 million in 2021. Administrative expenses increase to GBP7.4 million from GBP6.0 million a year earlier. Research & development expenditure amounts to GBP4.9 million, up from GBP3.7 million in 2021. Looking ahead, Destiny Pharma says it will focus on completing the manufacturing scale-up to deliver clinical trial material for the NTCD-M3 clinical programme being run by our partner Sebela. Chief Executive Officer Neil Clark says: "Destiny Pharma has made good progress in 2022 and in the first quarter of 2023."
Current stock price: 30.10 pence, down 1.3% on Thursday afternoon in London
12-month change: down 39%
By Xindi Wei, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Destiny Pharma. (DEST)